September 24, 2015—The senior Democrat on the House Oversight Committee asked the head of Turing Pharmaceuticals yesterday for all documents about the company's 340B pricing of Daraprim – which Turing recently bought from another company and immediately raised the price of by over 5,000 percent. … [Read more...]
Clinton Releasing Plan for Lowering Prescription Drug Costs
Drug pricing has become a marquee issue in the Democratic race for presidentSeptember 22, 2015—Democratic presidential candidate Hillary Clinton is releasing a multi-point plan today "to hold drug companies accountable to lower drug costs for Americans." … [Read more...]
Think Tank Recommends Policies to Rein in Drug Costs
Plan relies more on incentives than on direct price controlsSeptember 21, 2015—A think tank aligned with the Democratic Party has published a 45-page plan aimed at cutting prescription drug costs and giving drugmakers a bigger incentive to bring highly effective products to market. … [Read more...]
Key 340B Services Likely Would Remain Accessible During a Federal Shutdown
340B database and Regulations.gov portal stayed open during last shutdown in 2013September 18, 2015—For the second time in two years, a spending disagreement in Congress could force the government to shut down on the first day of October – which also is the start of one of the four 15-day periods per year for healthcare providers to enroll in the 340B drug discount program. … [Read more...]
Drugmakers Comment on 340B Pricing and Monetary Penalty Proposed Rule
PhRMA and BIO urge HRSA to make revisionsSeptember 16, 2015—The two major associations of brand-name drugmakers have issues with a proposed 340B program rule setting standards for calculating ceiling prices and implementing civil monetary penalties for drugmakers that knowingly and intentionally overcharge for 340B drugs. … [Read more...]
Drugmaker Acknowledges Overcharging 340B Entities
Heritage Pharmaceuticals says purchases going back six years are affectedSeptember 15, 2015—Heritage Pharmaceuticals, a U.S.-based generic-drug manufacturer owned by the Indian drugmaker Emcure, has posted a notice on the 340B drug pricing program website stating it "recently determined that 340B pricing to participating 340B covered entities was not extended on purchases of its products made between April 18, 2008 and December 31, 2014." … [Read more...]
Lawmakers File Comprehensive Bill to Cut Prescription Drug Prices
Sen. Sanders' campaign for president raises the issue's visibilitySeptember 11, 2015—Two members of Congress who have been investigating rising generic drug prices have introduced comprehensive legislation to make generic and brand-name medicines more affordable. … [Read more...]